News headlines about Affimed (NASDAQ:AFMD) have trended somewhat positive on Saturday, Accern reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Affimed earned a news impact score of 0.14 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.5968181992182 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
A number of equities analysts have recently issued reports on the company. Oppenheimer reissued a “hold” rating on shares of Affimed in a research note on Friday, November 24th. ValuEngine downgraded Affimed from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.
Affimed (NASDAQ:AFMD) opened at $1.30 on Friday. The stock has a market capitalization of $56.96, a P/E ratio of -1.67 and a beta of 3.49. Affimed has a one year low of $1.15 and a one year high of $2.95. The company has a debt-to-equity ratio of 0.14, a quick ratio of 6.39 and a current ratio of 6.43.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Affimed (AFMD) Stock Price” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://weekherald.com/2017/12/30/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-affimed-afmd-stock-price.html.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.